BOT Stock Overview
Botanix Pharmaceuticals Limited engages in the research and development of dermatology and antimicrobial products in Australia.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Botanix Pharmaceuticals Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.21 |
| 52 Week High | AU$0.24 |
| 52 Week Low | AU$0.077 |
| Beta | 1.84 |
| 1 Month Change | 10.26% |
| 3 Month Change | 26.47% |
| 1 Year Change | 133.70% |
| 3 Year Change | 155.95% |
| 5 Year Change | 104.76% |
| Change since IPO | 616.67% |
Recent News & Updates
Recent updates
Shareholder Returns
| BOT | AU Pharmaceuticals | AU Market | |
|---|---|---|---|
| 7D | -2.3% | -1.7% | 0.9% |
| 1Y | 133.7% | 31.3% | 5.6% |
Return vs Industry: BOT exceeded the Australian Pharmaceuticals industry which returned 31.3% over the past year.
Return vs Market: BOT exceeded the Australian Market which returned 5.6% over the past year.
Price Volatility
| BOT volatility | |
|---|---|
| BOT Average Weekly Movement | 7.1% |
| Pharmaceuticals Industry Average Movement | 10.9% |
| Market Average Movement | 8.9% |
| 10% most volatile stocks in AU Market | 17.6% |
| 10% least volatile stocks in AU Market | 3.5% |
Stable Share Price: BOT has not had significant price volatility in the past 3 months.
Volatility Over Time: BOT's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1984 | 11 | Howie McKibbon | www.botanixpharma.com |
Botanix Pharmaceuticals Limited engages in the research and development of dermatology and antimicrobial products in Australia. The company engages in development of novel treatments for common skin diseases and infections. Its product pipeline includes Sofpironium Bromide, a drug in development for the treatment of primary axillary hyperhidrosis that has completed Phase 3 clinical programs; BTX 1503, a transdermal gel formulation for the treatment of serious acne in adults and teenagers that has completed Phase II clinical trials; BTX 1801, which has completed Phase IIb clinical trials for the treatment of staphylococcus aureus and methicillin resistant staphylococcus aureus; BTX 1702 that is in Phase II clinical trials for the treatment of papulopustular rosacea; and BTX 1204A for the treatment of atopic dermatitis.
Botanix Pharmaceuticals Limited Fundamentals Summary
| BOT fundamental statistics | |
|---|---|
| Market cap | AU$338.65m |
| Earnings (TTM) | -AU$10.02m |
| Revenue (TTM) | AU$437.22k |
774.6x
P/S Ratio-33.8x
P/E RatioIs BOT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BOT income statement (TTM) | |
|---|---|
| Revenue | AU$437.22k |
| Cost of Revenue | AU$1.61m |
| Gross Profit | -AU$1.18m |
| Other Expenses | AU$8.85m |
| Earnings | -AU$10.02m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.0064 |
| Gross Margin | -269.36% |
| Net Profit Margin | -2,292.73% |
| Debt/Equity Ratio | 0% |
How did BOT perform over the long term?
See historical performance and comparison